Delaware Clinical and Translational Research ACCEL Program (Pilot Core)

摘要-试点项目方案 Accel-CTR计划建立了一个由临床医生和科学家组成的异常强大的网络，即 在特拉华州加强临床和转化性研究。在ACCEL3，也就是我们的第三个资金周期， 我们将继续扩大我们的影响，同时加强我们在关键领域的重点，包括创建 特拉华州临床和转化研究的可持续基础设施，建立科学的 重视多样性并将卫生公平作为重点的文化，以及社区的扩大 从事研究。在此次续订中，试点项目计划(PPP)将在过去的基础上不断发展和发展 取得的成功、吸取的教训以及对调查员和社区需求的回应。《公约》的具体目标 PPP的目的是(1)激励和支持临床和转化性研究；(2)促进高影响力的跨学科 合作；以及(3)帮助研究人员克服在整个研究中成功翻译的障碍 连续体。我们将为各种类型的奖励提供资金，包括标准试点补助金、试点补助金 特别针对社区参与的研究、跨学科拨款、导师奖和更大的 用于基础设施的赠款。作为对整个特派团的直接支持，公私合作伙伴关系将提出新的要求。 与多样性、卫生公平和社区参与有关。申请的评审工作将由 由有资质和经验的美国国立卫生研究院科学界成员使用评审和评分进行同行评审 机制是以美国国立卫生研究院为模型的。我们将优先考虑临床和社区参与的研究以及 解决影响医疗服务不足或不成比例地影响健康的情况的项目 特拉华州人。PPP将继续与其他Accel核心协同工作，以利用专业 发展机会、社区参与和外联职能，以及其他设施和服务，以 最大限度地提高我们的飞行员获奖者的培训和职业发展。PPP将由Susanne Morton领导 并得到Accel研究委员会的支持，所有伙伴机构都有代表，以及 行政人员。在ACCEL3中，PPP将继续成为完整的CTR核心，催化协作和 以社区为基础的临床和转化性研究，造福所有特拉华州人。

ABSTRACT- PILOT PROJECTS PROGRAM The ACCEL-CTR Program has established an exceptionally strong network of clinicians and scientists that is enhancing clinical and translational research within the state of Delaware. In ACCEL3, our third funding cycle, we will continue to broaden our impact while also sharpening our focus in key areas including the creation of sustainable infrastructure for clinical and translational research in Delaware, the establishment of a scientific culture that values diversity and incorporates health equity as a focus, and the expansion of community engaged research. In this renewal, the Pilot Projects Program (PPP) will grow and evolve based on past successes, lessons learned, and responding to investigator and community needs. The Specific Aims of the PPP are to (1) inspire and support clinical and translational research; (2) facilitate high-impact interdisciplinary collaborations; and (3) help investigators overcome barriers in successful translation across the research continuum. We will fund a wide variety of types of awards, including standard pilot grants, pilot grants specifically targeting community-engaged research, interdisciplinary grants, mentored awards, and larger grants for infrastructure. In direct support of the overall mission, the PPP will put in place new requirements related to diversity, health equity, and community engagement. Evaluation of applications will be conducted by peer-review by qualified and NIH-experienced members of the scientific community using review and scoring mechanisms modeled after the NIH. We will prioritize clinical and community engaged research as well as projects addressing conditions that affect the medically underserved or disproportionately affect the health of Delawareans. The PPP will continue to synergize with the other ACCEL cores to leverage professional development opportunities, community engagement and outreach functions, and other facilities and services to maximize the training and career development of our pilot awardees. The PPP will be led by Susanne Morton and supported by the ACCEL Research Committee, with representation from all partner institutions, and administrative staff. In ACCEL3, the PPP will continue to be an integral CTR core, catalyzing collaborative and community-based clinical and translational research for the benefit of all Delawareans.